3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Triple Negative Breast Neoplasms
2
Colonic Neoplasms
2
Thyroid Neoplasms
1
Polycystic Ovary Syndrome
1
Peritoneal Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pain
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Monoclonal Gammopathy of Undetermined Significance
1
Hypothyroidism
1
Hyperphagia
1
Hematologic Neoplasms
1
Goiter
1
Fallopian Tube Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Cancer Pain
1
Breast Neoplasms
1
Interventions
Paclitaxel
16
Carboplatin
14
Cisplatin
12
Oxaliplatin
9
Hyperthermic Intraperitoneal Chemotherapy
9
Cytoreduction Surgical Procedures
9
Fluorouracil
7
Bevacizumab
7
Doxorubicin
5
Leucovorin
4
Gemcitabine
4
catumaxomab
3
Docetaxel
3
Albumin-Bound Paclitaxel
3
130-nm albumin-bound paclitaxel
3
nintedanib
2
liposomal doxorubicin
2
epothilone B
2
Surgical Procedures, Operative
2
Palliative Care
2
Mitomycin
2
Laparoscopy
2
Interviews as Topic
2
Drug Therapy
2
Blood Specimen Collection
2
veliparib
1
tremelimumab
1
talimogene laherparepvec
1
strattice
1
sodium thiosulfate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Peritoneal Neoplasms
×
Glucose
×
Clear all
NCT03740165
2026-05-04
KEYLYNK-001
Merck Sharp & Dohme LLC
Phase 3
Completed
1,367 enrolled
29 charts